Yunpeng Pharmaceutical Group Co Ltd.

Primary objective: In accordance with relevant bioequivalence testing regulations, metoclopramide tablets (trade name: REGLAN, strength: 10mg), manufactured by ANI Pharmaceuticals, Inc., was selected as the reference formulation. A bioequivalence study was conducted on the test formulation, metoclopramide tablets (strength: 10mg), manufactured and supplied by Yunpeng Pharmaceutical Group Co., Ltd., under both fasting and postprandial administration conditions. The study aimed to compare the absorption rate and extent of the drug in the test formulation with those in the reference formulation to determine if the differences were within acceptable limits, and to evaluate the bioequivalence of the two formulations under fasting and postprandial administration conditions. Secondary objective: To observe the safety of oral administration of the test formulation metoclopramide tablets (strength: 10mg) and the reference formulation metoclopramide tablets (trade name: REGLAN, strength: 10mg) in healthy volunteers.

Primary Objective: In accordance with relevant bioequivalence testing regulations, betahistine mesylate tablets (trade name: Minsilan®; strength: 6mg), certified by Eisai (China) Pharmaceutical Co., Ltd., were selected as the reference formulation. A human bioequivalence study was conducted on the test formulation betahistine mesylate tablets (strength: 6mg), manufactured and supplied by Yunpeng Pharmaceutical Group Co., Ltd., under fasting and postprandial administration conditions. The study compared the absorption rate and extent of absorption of the drug in the test formulation with those in the reference formulation to determine if the differences were within acceptable ranges, and evaluated the bioequivalence of the two formulations under fasting and postprandial administration conditions. Secondary Objective: To observe the safety of oral administration of the test formulation betahistine mesylate tablets (strength: 6mg) and the reference formulation betahistine mesylate tablets (trade name: Minsilan®; strength: 6mg) in healthy subjects.

Main research objective: In accordance with relevant bioequivalence testing regulations, aminophylline tablets (trade name: Neophyllin®, specification: 100mg) certified by Alfres Farm Co., Ltd. were selected as the reference formulation. A preliminary human bioequivalence study was conducted on the test formulation aminophylline tablets (specification: 0.1g (calculated as C2H8N2(C7H8N4O2)2·2H2O)) manufactured and supplied by Yunpeng Pharmaceutical Group Co., Ltd., under fasting administration. The pharmacokinetic behavior of the two formulations in healthy participants in Chinese trials was compared, and the likelihood of bioequivalence between the two formulations under fasting administration conditions was assessed, providing a reference for the design of the formal trial. Secondary study objective: To observe the safety of oral administration of the test formulation aminophylline tablets (strength: 0.1g (calculated as C2H8N2(C7H8N4O2)2·2H2O)) and the reference formulation aminophylline tablets (trade name: Neophyllin®, strength: 100mg) in healthy participants.